Proteinases of betaretroviruses bind single-stranded nucleic acids through a novel interaction module, the G-patch  by Švec, Martin et al.
FEBS 28840 FEBS Letters 576 (2004) 271–276Proteinases of betaretroviruses bind single-stranded nucleic acids
through a novel interaction module, the G-patchMartin Sveca,b, Helena Bauerovaa, Iva Pichovaa, Jan Konvalinkaa,c,*, Kvido Strısovskya,1
aDepartment of Protein Biochemistry, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic,
Flemingovo n. 2, Praha 6, 166 10, Czech Republic
bDepartment of Theoretical Chemistry, Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic,
Flemingovo n. 2, Praha 6, 166 10, Czech Republic
cDepartment of Biochemistry, School of Natural Science, Charles University, Hlavova 2030, Praha 2, 128 43, Czech Republic
Received 30 July 2004; revised 27 August 2004; accepted 8 September 2004
Available online 18 September 2004
Edited by Hans-Dieter KlenkAbstract Retroviral proteinases (PRs) are essential for retro-
virus infectivity but the mechanism of their activity regulation is
poorly understood. We investigated possible involvement in this
process of the C-terminal domain (CTD) of betaretroviral PRs.
We found that the presence of CTD attenuates proteolytic
activity of Mason-Pﬁzer monkey virus PR, while it does not
signiﬁcantly aﬀect the activity of mouse intracisternal A-particle
retrovirus PR. However, both PRs bind single-stranded nucleic
acids through their CTDs that contain a novel binding motif, the
G-patch, whose function is dependent on a single conserved
tyrosine residue. Oligonucleotide binding to both PRs does not
inhibit their proteolytic activity.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Retroviruses express their aspartic proteinase (PR) as a part
of polyprotein precursors. At the late stage of viral life cycle,
PR is activated in the newly released immature virus particles
and it cleaves viral polyproteins into individual functional
components [1]. PR activity and its precise timing are essential
for virus infectivity [2–4] and, in fact, the HIV-1 PR inhibitors
are eﬃcient virostatics (see [5–7] for recent detailed reviews).
However, the mechanism of activation and activity regulation
of retroviral PRs has not been fully understood to date.
Retroviral PRs are active only as homodimers. A current
model for PR activation mechanism considers concentration-
dependent dimerisation of polyprotein precursors to be the
main factor contributing to PR activation in vivo. However,
additional factors seem to play a role, such as the redox po-
tential of the environment [8,9] or the cellular site of poly-
protein assembly [10,11]. Whereas most retroviruses assemble
and bud their capsids directly at the plasma membrane, a* Corresponding author.
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strisovk@uochb.cas.cz (K. Strısovsky).
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doi:10.1016/j.febslet.2004.09.010retrovirus family known as betaretroviruses assemble in the
cytosol. Their immature capsids are transported to the plasma
membrane and their PR is activated only after the virus release
from the cell [12]. This suggests that betaretroviral PR activity
regulation might employ other mechanisms in addition to the
concentration-dependent dimerisation of polyprotein precur-
sors. Interestingly, betaretroviral PRs contain a conserved C-
terminal extension of a hitherto unknown function (Fig. 1)
that extends beyond the retroviral PR homology domain and
might be involved in such a regulation mechanism.
A recent bioinformatic analysis of sequence data identiﬁed a
previously unnoticed, conserved glycine-rich domain, named
G-patch, in about 100 eukaryotic proteins and in betaretro-
viral polyproteins [13]. Importantly, the G-patch domain is
located within the C-terminal extension of betaretroviral PRs.
The G-patch domain has been proposed to have an RNA
binding aﬃnity, based on the fact that some of the eukaryotic
G-patch containing proteins have been implicated in RNA
processing [13], although no experimental data have been
provided. Hence, there is an intriguing possibility that the
activity of betaretroviral PRs might be regulated by nucleic
acid ligands. In this report, we examine this hypothesis by
investigating the role of the C-terminal domain (CTD) and its
possible interaction with nucleic acids for regulation of beta-
retroviral PR activity. For this purpose, we use two model PRs
from related betaretroviruses: mouse intracisternal A-type
particles endogenous retrovirus (MIA-14) and Mason-Pﬁzer
monkey virus (MPMV).2. Materials and methods
2.1. Oligonucleotides and chemicals
The following DNA oligonucleotides (ONs) were used for DNA
cloning:
F1: 50-GGGGTACCCATATGTTGGTTGTATCTTTAAATG-30,
R1 (T7-terminator): 50-GCTAGTTATTGCTCAGCGG-30,
R2: 50-GGGGATCCTCGAGCTATCAGGCGTTTTCATTGG-
30,
F3: 50-GTAACTGCTTAAATGTTAGCC-30,
R3: 50-GGCTAACATTTAAGCAGTTAC-30,
YS1F: 50-GGCAAAGATGGGTTCGAAAGAAGGAAAAGGG-
30,
YS1R: 50-CCCTTTTCCTTCTTTCGAACCCATCTTTGCC-30,
YS2F: 50-AGCCCAGGGCTCCAGCCCGGGAAAAGGGTTA
GG-30, andblished by Elsevier B.V. All rights reserved.
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30.
The following ONs were used for the electrophoretic mobility shift
assay:
DNA ONs:
1: 50-CACCTACACAAAGTGAGCTAGCTCTACGATCCGGT-
GTTTCGTCCTTTCCACAAG-3,
2: 50-CTGCCGACGCTCAACGAGACTCCCGAACAGGTTTG-
CCA-30,
3: 50-GATTAGGAATTGTGGAACCAATAGAAAATATTTAC-
30,
4: 50-GACCGCTCGGGCCCGAAGACAAGTACCGAG-30,
5: 50-TCGAGAGAGAGGATATTAAGAGTTGCAAAGATTTT-
TTTTAATTCTGTTTC- 30,
6: TGGCAAACCTGTTCGGGAGTCTCGTTGAGCGTCGGC-
AG
RNA ONs:
7: 50-GGACUAGCGGAGGCUAGUCC-30, and
8: 50-UCCUAGGUGAGUGAGACGUGUGCUU-30.
All ONs were custom-synthesised on solid phase support and
HPLC-puriﬁed. All other chemicals were of analytical grade.
2.2. Cloning
The DNA cloning was performed by standard methods [14]; site-
directed mutagenesis was carried out using the Quick-change protocol
(Stratagene) and the authenticity of all clones was conﬁrmed by DNA
sequencing.
MIA-14 PR variants were subcloned by PCR using the NcoI frag-
ment of MIA-14 genome inserted in the pET16b expression vector as a
template [15]. The full length MIA-14 PR expression construct was
generated using the F1 and R1 primers that removed the 50-end of PR
precursor gene to encode mature MIA-14 PR [15]. The PCR product
was cloned into pET22b expression vector (Novagen) between NdeI
and NcoI sites to yield pET_MIAPR. The expression construct for the
C-terminally truncated MIA-14 PR (MIA-14 PRDCTD) was gener-
ated using the F1 and R2 primers that introduced stop codon after the
Ala109 codon of mature MIA-14 PR (Fig. 1, symbol 1). The resulting
PCR product was inserted between NcoI and XhoI sites of pET22b
expression vector to yield pET_MIAPRDCTD.
The expression plasmid for the C-terminally truncated M-PMV PR
(M-PMV PRDCTD) was prepared by site-directed mutagenesis using
pBP construct as a template [16,17] and the F3 and R3 primers that
introduced a stop-codon at the 30-end of M-PMV PRDCTD gene. The
corresponding M-PMV PRDCTD protein spans amino acids 1–114 of
the mature M-PMV PR (Fig. 1, symbol 2) and it is identical to PR13
from that described in [17].
The MIA-14 PR Tyr126Ser mutant was generated by site-directed
mutagenesis of the pET_MIAPR template using the YS1F and YS1R
primers that changed the TAT (Tyr126) codon into TCG (Ser126) and
introduced a unique BstBI restriction site. The MPMV PR Tyr121Ser
mutant was constructed analogously, using pBP plasmid as a templateFig. 1. The C-terminal extension of betaretroviral PRs extends beyond the r
patches. Multiple protein sequence alignment of mature MIA-14 PR [15], MP
PR (UniProt Accession No. 012834) was generated using the ClustalW so
background, identical residues on a dark grey background, and the residues
ground. The retroviral PR homology domain is deﬁned by the sequence of len
and 2 show the boundaries between the PR domain and the CTD of MIA-14
Ser in MIA-14 PRY126S and MPMV PRY121S is enclosed in a black box.[16,17] and the YS2F and YS2R primers that changed the TAC
(Tyr121) codon into TCC (Ser121).
2.3. Recombinant protein expression and puriﬁcation
MIA-14 PR, MIA-14 PRY126S and MIA-14 PRDCTD were ex-
pressed in Escherichia coli BL21(DE3) using the T7 promoter/T7 RNA
polymerase transcription/translation system [18]. Suspension culture of
transformed E. coli cells was grown at 37 C in Luria–Bertani medium
[14] supplemented with 100 lg/ml ampicillin. Recombinant protein
expression was induced at culture OD600 value of 0.8 by the addition of
0.5 mM isopropyl-b-D-thiogalactopyranoside. After 3 h of induction,
bacteria were pelleted by centrifugation and frozen to )20 C. To
isolate recombinant proteins, bacterial cells were resuspended in a lysis
buﬀer (50 mM Tris–HCl, 50 mM NaCl, 1 mM EDTA, and 1 mM
phenylmethylsulfonyl ﬂuoride, pH 8.0) at circa 0.1 g cell paste per ml
and desintegrated as described [15].
MIA-14 PR and MIA-14 PRY126S were isolated from the soluble
fraction of the bacterial lysate. It was dialysed against 100 volumes of 50
mM Tris–HCl, 1 mM EDTA, 0.05% (v/v) 2-mercaptoethanol and 10%
(v/v) glycerol, pH 8.5, at 4 Covernight and the dialysate was clariﬁed by
centrifugation. The PR variants were further puriﬁed by liquid chro-
matography using Q-Sepharose, SP-Sepharose Fast Flow and Superdex
75HR (all Pharmacia) columns and handled as described [15].
MIA-14 PRDCTD was isolated from the insoluble portion of the
induced bacterial lysate. The collected and washed [19] inclusion
bodies were resuspended in 200 mM Tris–HCl, 100 mM sodium
phosphate, 0.5% (v/v) 2-mercaptoethanol, and 20 mM EDTA, pH 7.0,
at 0.3 g per ml and diluted 10-fold in freshly prepared 8 M urea heated
to 40 C. The suspension was stirred for 30 min and MIA-14 PRDCTD
was refolded by dialysis into 50 mM Tris–HCl, 4 mM EDTA, 8% (v/v)
glycerol, and 0.1% (v/v) 2-mercaptoethanol, pH 7.5, at 4 C and then
into SP buﬀer (50 mM sodium acetate, 20 mM NaCl, and 0.05%
mercaptoethanol, pH 5.0). The dialysate was clariﬁed by centrifuga-
tion (30 000·g, 15 min, 4 C) and puriﬁed on an SP-Sepharose Fast
Flow column (Pharmacia) with elution by a linear gradient of 0–1 M
NaCl in SP buﬀer. The eluted fractions containing MIA-14 PRDCTD
were pooled, dialysed against 50 mM sodium acetate, 200 mM NaCl, 2
mM EDTA, 10% (v/v) glycerol and 0.05% (v/v) 2-mercaptoethanol, pH
5.5, concentrated by ultraﬁltration to circa 4 mg/ml and further puri-
ﬁed on a Superdex 75HR gel ﬁltration FPLC column (Pharmacia) in
the same buﬀer.
All MPMV PR variants were expressed and puriﬁed as described
[20]. All proteins were stored at )70 C.
2.4. Activity assays and enzyme kinetics
Protein concentration was determined by the Coomassie dye binding
assay (Bio-Rad) and enzyme activities were measured at 37 C. The
activity of MIA-14 PR variants was followed in a continuous spec-
trophotometric assay using synthetic chromogenic peptide substrate
DSAYF(NO2)VVS that mimics the N-terminal MIA-14 PR auto-
processing site [15]. Substrate cleavage was monitored at 305 nm. Theetroviral PR homology domain and contains highly conserved glycine
MV PR (UniProt Accession No. P07570, residues 163–314) and HIV-1
ftware, version 1.82 [33]. Similar residues are shown on a light grey
conserved among all three PRs are shown in white on a black back-
tiviral HIV-1 PR. Legend: * denotes the active site catalytic aspartate, 1
and MPMV PR, respectively. The conserved Tyr that was mutated to
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tinuous assay using ATHQVYF(NO2)VRKA peptide substrate whose
cleavage was monitored by HPLC as described [20]. Kinetics constants
of the Michaelis–Menten equation were determined from the initial
reaction rates by non-linear regression ﬁtting into the appropriate
model equations using GraFit programme (Erithacus Software Ltd.,
Surrey, UK). The peptide substrates were synthesised on solid phase
and puriﬁed by reversed-phase HPLC.
2.5. Electrophoretic mobility shift assay
All solutions used for the electrophoretic mobility shift assay
(EMSA) experiments with RNA ONs were prepared using diethylpy-
rocarbonate-treated water. To facilitate detection, each DNA or RNA
ON (50 ng) was radiolabelled by 50-phosphorylation using T4 poly-
nucleotide kinase (New England Biolabs) and 20 lCi of [c-32P]ATP
(Amersham Biosciences). The labelled ONs were puriﬁed using
MicroSpin G-25 columns (Amersham Biosciences) and immediately
used for binding experiments. Labelled double-stranded DNA
(dsDNA) was generated by annealing labelled ON 6 and a 3-fold molar
excess of unlabelled ON 2 (that is complementary to ON 6), heating
the mixture to 96 C for 2 min and cooling it down to room temper-
ature within 2 h. In binding experiments, 2–7 nM labelled ON was
incubated in the presence of 1–2 lM tested protein for 45 min at room
temperature in 20 lL of reaction buﬀer (50 mM Tris–HCl, 4% (v/v)
Ficoll 400, pH 8.0). Protein–ON complexes, which always display
lower electrophoretic mobility than free ONs, were resolved by elect-
rophoresis in a native 6% polyacrylamide gel in 0.5 TBE running
buﬀer. Gels were dried and the radiolabelled material was detected by
autoradiography.3. Results
3.1. Cloning, expression and puriﬁcation of the full-length and
C-terminally truncated MIA-14 and MPMV PRs
We set out to study the possible role of the C-terminal ex-
tension in activity regulation of betaretroviral PRs. To this end
we subcloned the C-terminally truncated MIA-14 and M-PMV
PRs (designated MIA-14 PRDCTD and MPMV PRDCTD)
into prokaryotic expression vectors based on their described
N- and C-terminal autocleavage sites [15,20,21] and amino
acid alignments of retroviral PRs (Fig. 1). All PRs wereFig. 2. (A) Purity of the recombinant MIA-14 and MPMV PR variants used
each enzyme per lane. Molecular weight markers are shown on the left. Partia
[15]. (B) The pH dependence of catalytic eﬃciency (Vmax/(E0KM)) of MIA-1
DSAYF(NO2)VVS that mimicks the N-terminal MIA-14 PR precursor autop
2.4. The reaction buﬀer contained 100 mM buﬀer ion, 1 mM ethylenediaminheterologously overexpressed in E. coli. While MIA-14 PR
variants were isolated from the soluble part of bacterial extracts
in a folded and active state, MIA-14 PRDCTD was expressed
into bacterial inclusion bodies. The enzyme was isolated and in
vitro refolded by urea-induced denaturation and gradual re-
moval of the denaturant by dialysis. The eﬃciency of refolding
was conﬁrmed by gel-permeation chromatography where pu-
riﬁed MIA-14 PRDCTD migrated as a symmetric peak, which
is characteristic for a folded protein (data not shown). The
MIA-14 PR variants were further puriﬁed in a series of chro-
matographic steps to yield highly puriﬁed preparations
(Fig. 2A). The MPMV PR and its mutants accumulated in
inclusion bodies during expression in E. coli and they were
isolated, in vitro refolded, and puriﬁed as described [20]
(Fig. 2A). All protein preparations exhibited 280 nm/260 nm
absorbance ratio in the range of 1.6–1.8, which is in accordance
with the estimated values computed from the amino acid
composition of PRs and absorption spectra of free amino acid
chromophores Trp, Tyr and Phe [22], indicating the absence of
signiﬁcant amounts of endogenous nucleic acid contamination.
3.2. The inﬂuence of CTD on the proteolytic activity of MIA-14
and MPMV PRs
To determine the eﬀect of betaretroviral PR CTD of pro-
teolytic activity, we measured the Michaelis–Menten kinetics
parameters and their pH dependence for both the wild type
and truncated PR variants using puriﬁed enzymes and peptide
substrates in vitro. As no tight-binding inhibitors that would
allow the determination of accurate concentration of the active
enzyme were available for either PR, we approximated kcat by
Vmax/E0 assuming the absence of any inactive enzyme species
in our preparations.
The presence of the C-terminal extension in both MIA-14
and MPMV PRs does not inﬂuence the enzymes’ pH optima
that remain in the acidic range. The pH optimum of catalytic
eﬃciency Vmax/(E0KM) is at pH 5.3 for both the full-length
and the C-terminally truncated MIA-14 PR (Fig. 2B). Whilein this study. Coomassie-stained 18% SDS–PAGE gel shows 0.2 lg of
l autodegradation of some PR species within the CTD can be observed
4 PR and MIA-14 PRDCTD was determined using peptide substrate
rocessing site. Enzyme activity was determined as described in Section
etetraacetic acid (EDTA) and 2 M NaCl.
Table 1
Inﬂuence of the CTD on proteolytic activities of MIA-14 and MPMV
PRs
Enzyme KM (lM) Vmax/E0 (s1)
MIA-14 PR 5.9 0.6 1.81 0.05
MIA-14 PRDCTD 11.3 2.5 1.64 0.14
MPMV PR 36 5.1 0.24 0.04
MPMV PRDCTD 386 42 3.2 0.30
The activity of MIA-14 PR and MIA-14 PRDCTD was determined
spectrophotometrically at 37 C in a continuous assay, using peptide
substrate DSAYF(NO2)VVS that mimics the N-terminal MIA-14 PR
precursor autoprocessing site [15]. The reaction buﬀer of pH 5.3 con-
tained 100 mM sodium acetate, 1 mM ethylenediaminetetraacetic acid
(EDTA), 2 M NaCl and 0.05% (v/v) 2-mercaptoethanol. The activity
of MPMV PR and MPMV PRDCTD was determined by a discon-
tinuous assay using ATHQVYF(NO2)VRKA peptide substrate whose
cleavage was monitored by HPLC, as described [20]. The reaction
buﬀer of pH 5.3 contained 50 mM sodium acetate, 1 mM EDTA, 0.3
M NaCl and 0.05% (v/v) 2-mercaptoethanol. The initial reaction ve-
locities were ﬁtted into the Michaelis–Menten equation by non-linear
regression. The resulting kinetic constants are expressed as mean
values standard error of the mean.
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PRDCTD shows only slight and similar increase with pH, the
Vmax/E0 is strongly pH-dependent with a maximum at pH 5.3
(data not shown). The diﬀerences in KM or Vmax/E0 between
MIA-14 PR and MIA-14 PRDCTD are rather marginal,
maximum 2-fold within the studied pH interval. On the other
hand, MPMV PR variants display greater diﬀerences in ac-
tivity. Even though the catalytic eﬃciencies Vmax/(E0KM) of
MPMV PR and MPMV PRDCTD are almost identical,
MPMV PRDCTD displays about 10-fold higher KM and Vmax/
E0 than MPMV PR. Comparison of kinetic parameters of
MIA-14 and MPMV PR variants at their pH optima is sum-
marised in Table 1.Fig. 3. MIA-14 and MPMV-PRs bind ssDNA and RNA through their C-ter
shift assay (EMSA) polyacrylamide gel comparing the binding aﬃnity of the
and the PR variant mutated in the conserved tyrosine within CTD (PRY12
identical analysis for the MPMV PR. The protein–ON complexes that alway
separate bands in the top part of the gels. The EMSA experiments were carrie
MIA-14 PR to ss and ds DNA. Radioactively labelled (*) dsDNA was gener
ON 2 that is exactly complementary to ON 6. The addition of a 3-fold molar
intensity of the ON 6–PR complex band but does not abolish it, while the ad
labelled ON 6 leads to only dsDNA being visible on the EMSA gel and no PR
lower electrophoretic mobility than ssDNA.3.3. MIA-14 and MPMV-PRs bind single-stranded (ss) nucleic
acids through interactions with their CTDs
To analyse whether the putative nucleic acid binding do-
main, the G-patch [13], predicted to be present within the C-
terminal extension of betaretroviral PRs could bind nucleic
acids, we performed electrophoretic mobility shift assay
(EMSA) using puriﬁed PR variants and ﬁve DNA and two
RNA ONs varying in length and GC content. In all cases, we
observed ON binding only to full-length PRs and not to their
C-terminally truncated variants, demonstrating that nucleic
acid binding to both betaretroviral PRs is mediated by their
CTDs. Both MIA-14 and MPMV PRs bind DNA ONs 1–5
whose lengths range from 30 to 54 bases, and GC content from
approximately 30–70% with comparable eﬃciency, showing
the absence of a clear sequence speciﬁcity of binding to ssDNA
(see Fig. 3A and B for ON 1 and Fig. 3C for ON 6 as exam-
ples). However, while MIA-14 PR binds both RNA ONs 7 and
8, the MPMV PR binds only ON 8. Furthermore, the MIA-14
PR forms three complexes with RNA ON 8 that diﬀer in
electrophoretic mobility, while MPMV PR forms only the
lowest mobility complex with ON 8. This might be caused by
diﬀerent binding stoichiometry of PR–ON complexes and/or
the presence of various conformational isomers of ON 8. Both
observations together suggest that the two G-patch domains
might have distinct binding speciﬁcities.
Next, we directly compared the aﬃnities of PR binding to
ssDNA and dsDNA. In this experiment, the addition of a 3-
fold molar excess of unlabelled ON 6 over the labelled ON 6
partially decreases the intensity of the ON 6–MIA-14 PR
complex band but does not abolish it, while the addition of 3-
fold molar excess of unlabelled complementary ON 2 over
labelled ON 6 leads to only the dsDNA being visible on the
EMSA gel and no ON 6–PR complexes being observable
(Fig. 3C).minal extension. (A) Autoradiogramme of the electrophoretic mobility
full-length MIA-14 PR, its C-terminally truncated mutant (PRDCTD)
6S) to DNA ON 1 and RNA ONs 7 and 8. (B) EMSA gel showing
s have lower electrophoretic mobility than free ONs can be observed as
d out as described in Section 2.5. (C) Comparison of binding aﬃnity of
ated by labelling ssDNA ON 6 and adding 3-fold excess of unlabelled
excess of unlabelled ON 6 over the labelled ON 6 partially decreases the
dition of 3-fold molar excess of unlabelled complementary ON 2 to the
–ON 6 complexes being observable. Notice that dsDNA has a slightly
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MIA-14 PR is a speciﬁc property of the domain structure, we
selected a highly conserved aromatic residue that is present in
all analysed G-patch domains [13], assuming that it might be
important for the domain function, and mutated it to Ser. We
have prepared recombinant MIA-14 PRY126S and MPMV
PRY121S and tested their nucleic acid binding properties using
EMSA. While the proteolytic activity of both mutant PRs was
not aﬀected, we could not detect any signiﬁcant binding af-
ﬁnity of MIA-14 PRY126S and MPMV PRY121S to nucleic
acids (Fig. 3A and B). This conﬁrms that the binding of be-
taretroviral PR to nucleic acids is mediated speciﬁcally by the
G-patch domain, and that its conserved Tyr residue is im-
portant for binding speciﬁcity or for maintaining domain
structure.
3.4. Nucleic acid binding to MIA-14 and MPMV PRs does not
signiﬁcantly aﬀect their proteolytic activity
To analyse whether nucleic acid binding to the CTD of
MIA-14 PR could modulate proteolytic activity of the PR
domain, we determined the inﬂuence of a 5.4-fold molar excess
of ON 2 on the activity of MIA-14 and MPMV PR, PRDCTD,
and PRY! S. In the presence of ON 2, MIA-14 PR activity
increased to 148%, MIA-14 PRDCTD to 118% and MIA-14
PRY126S only to 103% relative to the activity of the respective
enzyme in the absence of ON 2 (Fig. 4). On the other hand, the
activity of MPMV PR, MPMV PRDCTD, and MPMV
PRY121S was not inﬂuenced by ON 2 binding at all. The slight
activatory eﬀect of ON 2 on MIA-14 PRDCTD might be non-
speciﬁc and due to a lower stability of MIA-14 PRDCTD
relative to MIA-14 PR, since we observed a similar eﬀect
caused by the polyanionic polymer heparin (not shown). The
activity of PRY! S mutants that do not bind any ONs in our
EMSA assays is practically not aﬀected by the presence of ONFig. 4. The inﬂuence of nucleic acid binding on MIA-14 PR and
MPMV PR proteolytic activity. The activity of MIA-14 PR variants
(grey bars) and MPMV PR variants (white bars) was determined in the
presence of 5.4-fold molar excess of ON 2 and expressed relative to the
activity of the respective enzyme in the absence of ON 2. Reaction
mixtures contained 250 nM enzyme, 1.35 lM ON 2, 100 mM sodium
acetate, pH 5.3, 100 mM NaCl and 0.05% (v/v) 2-mercaptoethanol.
After 20 min preincubation of the mixtures, proteolytic reaction was
started by the addition of 250 lM substrate peptide ATH-
QVYF(NO2)VRKA and allowed to continue for 10 min. Cleavage
products were separated and quantiﬁed by reversed-phase HPLC as
described [17]. Each value was determined in triplicates and the results
are expressed as the mean value standard error of the mean.2. In conclusion, a randomly chosen DNA ON 2 that binds to
MIA-14 and MPMV PRs (Fig. 3C) does not have signiﬁcant
inﬂuence on their activities.4. Discussion
The mechanism of activity regulation of retroviral PRs is
still poorly understood. Betaretroviruses are excellent models
for studying PR activation because the processes of their
polyprotein assembly and PR activation are spatially and
temporally separated. In those particular examples of beta-
retroviruses that we studied, the MPMV virus particles form in
the cytoplasm and are proteolytically processed only after vi-
rus budding from the cell, while MIA-14 endogenous retrovi-
rus particles assemble and bud through the endoplasmic
reticulum membrane, accumulate inside the ER and are never
proteolytically processed there. Betaretroviral PRs, unlike the
lentiviral PRs, might utilise an additional control mechanism
to delay their activation until viral budding occurs. Interest-
ingly, betaretroviral PRs contain an 50 amino acid long C-
terminal extension that is not present in other retroviral PRs.
In this report, we investigated the potential role of the C-ter-
minal extension in regulation of betaretroviral PR activity.
The ‘‘economy’’ of organisation of retroviral genomes sug-
gests that it would be unlikely that a conserved protein domain
would not serve any purpose. Several PRs of betaretroviruses
and related endogenous retroviruses that contain theC-terminal
extension, such as MPMV, MIA-14, human endogenous retro-
virus K10 (HERV K10), and rabbit endogenous retrovirus H
[23], formerly known as human retrovirus 5 [24], have been
shown to undergo sequential processing from the C-terminus
both in vitro [15,21,23,25] and in vivo [20]. However, the func-
tional importance of this process has not been elucidated. TheC-
terminally truncated form ofHERVK10 PRwas shown to have
about 20-fold higher activity than the full-length form and the
authors thus hypothesised that PR C-terminal extension might
act as an intramolecular inhibitor [25]. In our experiments, the
C-terminally truncatedMIA-14PRhas about half of the activity
of the full-length MIA-14 PR, which would contradict that hy-
pothesis, but PR activity of an endogenous retrovirus might not
be relevant, since endogenous retrovirus polyproteins usually do
not undergo proteolytic processing inside the cells. On the other
hand, the observations regarding MPMV PR and MPMV
PRDCTD are in line with the above hypothesis. Although the
catalytic eﬃciencies Vmax/(E0KM) of MPMV PR and MPMV
PRDCTD are almost identical, the C-terminally truncated var-
iant MPMV PRDCTD displays about 10-fold higher KM and
Vmax/E0 than the full-length MPMV PR. In this respect, it
should be remembered thatwithin the virionwhere PR substrate
concentration is high, about 1 mM [26], PR will be substrate-
saturated and it is then the Vmax/E0 that determines its catalytic
power. Hence, in the case of MPMV PR, the presence of its C-
terminal extension may indeed act to down-modulate PR ac-
tivity in cis. However, this is unlikely to be its only role since less
than half of MPMV PR is C-terminally processed in the virions
[20].
A domain homologous to betaretroviral PR CTD has been
recently identiﬁed in over 100 eukaryotic proteins [13]. It
contains several conserved glycine residues and was therefore
named ‘G-patch’. It was suggested that this domain mediates
RNA-protein interactions, based on an indirect observation
276 M. Svec et al. / FEBS Letters 576 (2004) 271–276that many of the proteins in which it is present are implicated
in RNA processing. In this report, we provide direct proof that
the G-patch domain located within the C-terminal extension of
betaretrovirus PRs eﬃciently binds ss nucleic acids. We found
that its binding speciﬁcity might diﬀer between betaretrovi-
ruses and is strongly dependent on a conserved aromatic res-
idue (mostly Tyr) that might be involved in critical interactions
with nucleic acid bases [27].
The possibility that a PR function could be regulated by
interaction with a nucleic acid is not unique in the literature. It
has been observed previously that the cleavage of the p15NC
protein in HIV-1 by the HIV-1 PR is activated by viral RNA
or RNA ON binding to p15NC in vitro [28]. However, the
mutations in the RNA binding domain of p15NC introduced
into an infectious clone of HIV-1 only slightly delayed p15NC
processing without signiﬁcantly compromising virus morpho-
genesis [29]. In another, perhaps more relevant, example, the
coxsackievirus B3 PR 3C was shown to eﬃciently bind an
RNA element within the 50 non-translated region of the viral
RNA [30], which serves for the assembly of protein complexes
necessary for the initiation of cap-independent translation and
positive-strand RNA synthesis. However, the role of proteo-
lytic activity of the 3C PR in these protein complexes is unclear
at present [31].
We observed that the binding of a short ON to the CTD of
MIA-14 and MPMV PRs does not have any signiﬁcant activa-
tory or inhibitory eﬀects on the proteolytic activity (Fig. 4).
Thus, it appears that in a mature betaretroviral PR the two
domains, the PR domain and the G-patch, are functionally in-
dependent. We thus hypothesise that: (1) a long nucleic acid
molecule binding to the CTD of the PR monomer, that is still a
part of the viral polyprotein precursor, might interfere with PR
precursor domain dimerisation and subsequent PR activation in
virions and (2) after the ultimate PR activation and virion
maturation, the C-terminal extension of a mature betaretroviral
PR might target PR preferentially to its substrates that are as-
sociated with a nucleic acid. In support of the second point, it
should be pointed out that during translation of MPMV poly-
protein precursors, viral enzymes reverse transcriptase (RT) and
integrase are produced by a –1 ribosomal frameshift at the 30 end
of PR open reading frame [32]. The resulting GagProPol poly-
protein contains the G-patch domain inserted between the PR
and RT domains. It is possible that proteolytic processing of
GagProPol generates RT containing the G-patch domain at its
N-terminus. The presence of a G-patch in both PR and RT
might allow co-targeting of both enzymes to an RNA domain
and thus would facilitate a ‘‘directed’’ proteolytic processing of
RT or other associated proteins. It remains to be shownwhether
any of these two points are valid in vivo, i.e., whether the G-
patch domain might be important for the timing and extent of
proteolytic processing ofMPMVpolyproteins and/or activity or
speciﬁcity of MPMV RT.
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